Aarti Drugs Faces Soaring Costs, Restricts Orders to 8 Days

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorKavya Nair|Published at:
Aarti Drugs Faces Soaring Costs, Restricts Orders to 8 Days
Overview

Aarti Drugs is facing tough cost increases from crude oil and ammonia-based materials. To manage this, the pharmaceutical company is booking orders only for the next 8-10 days. While trying to share costs on current orders, it's pricing new sales much higher. Production is steady, but key ingredients for Metformin and Metronidazole are tight, affecting production goals. The company's approach of passing on some price hikes might not fully cover rising expenses, potentially hurting future profits.

The Cost Surge

Aarti Drugs' careful shift in how it books orders signals a weaker ability to set prices due to sharp increases in essential chemical costs. The company's stock activity suggests investors are cautious, weighing whether its strategy of adjusting prices can hold up against constant raw material price swings. The market's reaction shows it's focusing on these ongoing cost pressures more than the company's new booking methods.

Industry Context and Valuation

Aarti Drugs' price-to-earnings ratio stands at about 28.5, placing it in the typical range for Indian pharmaceutical API (Active Pharmaceutical Ingredient) makers, who usually trade between 25x and 30x. Rivals like Divi's Laboratories often achieve higher valuations because they offer strong contract manufacturing services and are more vertically integrated. The current rise in prices for crude oil and ammonia derivatives is a widespread industry challenge, affecting many chemical and drug inputs. Global political tensions are a key reason for this price volatility, increasing supply chain risks. In the past, similar cost inflation around March 2025 caused a temporary stock drop of 8-10% for Aarti Drugs. The company recovered by raising prices 5-7% and seeing competitors face similar issues. However, the current surge in costs is a more significant challenge to this pattern. Aarti Drugs' market value of approximately ₹28,000 crore shows its established position, but its dependence on buying materials from outside makes it more vulnerable to global commodity market swings than more integrated competitors.

Key Risks for Aarti Drugs

Aarti Drugs' decision to absorb half of the cost increase on existing orders directly affects its profits. This strategy could become unsustainable if input costs keep rising, forcing deeper price cuts or steep hikes on new orders that might drive customers away or hand market share to nimbler rivals. Unlike competitors who may have locked in long-term raw material supplies or use advanced hedging tools, Aarti Drugs' reliance on short-term bookings reveals a significant weakness. Additionally, while production is stable, issues with key ingredients for Metformin and Metronidazole indicate possible supply chain delays that could limit overall growth and impact important revenue sources.

Analyst Views and Outlook

Analysts are watching for signs that raw material prices will stabilize. Market sentiment is divided, with some keeping 'Hold' ratings because of margin worries and others sticking with 'Buy' ratings, citing strong long-term demand for APIs and Aarti Drugs' market standing. Price targets generally fall between ₹620 and ₹700, suggesting limited immediate growth until costs level out or the company regains its full pricing strength. The short-term outlook is closely linked to the unpredictable path of global commodity markets and Aarti Drugs' ability to adjust supply deals without sacrificing sales volume or future profits.

Disclaimer:This content is for informational purposes only and does not constitute financial or investment advice. Readers should consult a SEBI-registered advisor before making decisions. Investments are subject to market risks, and past performance does not guarantee future results. The publisher and authors are not liable for any losses. Accuracy and completeness are not guaranteed, and views expressed may not reflect the publication’s editorial stance.